A61K36/65

PHARMACEUTICAL COMPOSITION CONTAINING COMBINATION EXTRACTS OF MOUTAN ROOT BARK, ANGELICA DAHURICA ROOT, BUPLEURUM ROOT OR FRACTIONS THEREOF FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDER

The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting of Moutan Root Bark, Angelica Dahurica Root, and Bupleurum Root, or a fraction thereof. Specifically, the extract of the mixture of the present invention exhibits a recovery effect on mitochondrial function damage, a relieving effect on endoplasmic reticulum stress and also exhibits simultaneously an inhibitory effect on inflammatory response, which are remarkably improved compared with those exhibited in an in vitro single extract, and the extract of the mixture significantly exhibits an improvement effect on motor coordination and a protective effect on dopaminergic neurons in a Parkinson's disease animal model, and thus the extract of the mixture of the present invention or a fraction thereof can be useful as an active ingredient of a pharmaceutical composition for treating and preventing degenerative neurological disorders.

Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

Medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, preparation method therefor and use method thereof
20170319475 · 2017-11-09 ·

The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.

Medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, preparation method therefor and use method thereof
20170319475 · 2017-11-09 ·

The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.

Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

Pharmaceutical composition for preventing or treating diabetic complications and angioedema, containing natural mixture extract as active ingredient

The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy, and angioedema, including macular (retinal) edema, macular degeneration, and varicose veins.

Pharmaceutical composition for preventing or treating diabetic complications and angioedema, containing natural mixture extract as active ingredient

The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy, and angioedema, including macular (retinal) edema, macular degeneration, and varicose veins.